bullous pemphigoid

The FDA has opened the investigational new drug application for Phase 3 trial for Akari Therapeutics Plc's (NASDAQ: AKTX) lead drug candidate, nomacopan, for the treatment of moderate and severe Bullous Pemphigoid (BP), allowing clinical sites to open mid-2021, subject...

Shares of Immune Pharmaceuticals Inc (NASDAQ: IMNP) were trending last week, gaining as much as 76 percent in three days. With no material news surfacing, it seemed like the rally was driven by a recent article that featured the company. Shares have given up most of the gains on Thursday trading....